Cargando…

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV

On the basis of TP53 mutations and standardized uptake values (SUVs) from 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), we sought to enhance our knowledge of the biology underlying low progesterone receptor (PR) expression in estrogen receptor (ER)-positive/human epidermal growt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Sung Gwe, Yoon, Chang Ik, Lee, Jae Hoon, Lee, Hye Sun, Park, So Eun, Cha, Yoon Jin, Cha, Chihwan, Bae, Soong June, Lee, Kyung-A, Jeong, Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347277/ https://www.ncbi.nlm.nih.gov/pubmed/30407916 http://dx.doi.org/10.1530/ERC-18-0281

Ejemplares similares

Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer
por: Yoon, Chang Ik, et al.
Publicado: (2019)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
por: Ji, Jung Hwan, et al.
Publicado: (2022)

Radiotherapy-Induced High Neutrophil-to-Lymphocyte Ratio is a Negative Prognostic Factor in Patients with Breast Cancer
por: Yoon, Chang Ik, et al.
Publicado: (2020)

Relationship of the standard uptake value of (18)F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm
por: Park, Soeun, et al.
Publicado: (2021)

High A20 expression negatively impacts survival in patients with breast cancer
por: Yoon, Chang Ik, et al.
Publicado: (2019)

YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
por: Park, Inho, et al.
Publicado: (2023)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
por: Bae, Soong June, et al.
Publicado: (2021)

Comparison of complications according to incision types in nipple-sparing mastectomy and immediate reconstruction
por: Park, Soeun, et al.
Publicado: (2020)

High Nuclear Expression of Yes-Associated Protein 1 Correlates With Metastasis in Patients With Breast Cancer
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy
por: Bae, Soong June, et al.
Publicado: (2020)

Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Bae, Soong June, et al.
Publicado: (2022)

Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer
por: Lee, Yangkyu, et al.
Publicado: (2022)

The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
por: Cha, Yoon Jin, et al.
Publicado: (2022)

Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2019)

Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence After Breast Conserving Surgery With Sentinel Lymph Node Biopsy: Pooled Analysis Using Data From a Systematic Review and Two Institutions
por: Yoon, Chang Ik, et al.
Publicado: (2020)

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Clinical Features of Breast Cancer in South Korean Patients with Germline TP53 Gene Mutations
por: Alyami, Hassan, et al.
Publicado: (2021)

A nomogram constructed using intraoperative ex vivo shear-wave elastography precisely predicts metastasis of sentinel lymph nodes in breast cancer
por: Bae, Soong June, et al.
Publicado: (2019)

Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2020)

Author Correction: Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2021)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
por: Baek, Seung Ho, et al.
Publicado: (2022)

Metastasis Risk Assessment Using BAG2 Expression by Cancer-Associated Fibroblast and Tumor Cells in Patients with Breast Cancer
por: Yoon, Chang-Ik, et al.
Publicado: (2021)

(18)F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence
por: Kim, Hyun Jeong, et al.
Publicado: (2022)

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
por: Andersen, TI, et al.
Publicado: (2000)

Immediate Breast Reconstruction Does Not Have a Clinically Significant Impact on Adjuvant Treatment Delay and Subsequent Survival Outcomes
por: Baek, Seung Ho, et al.
Publicado: (2019)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer
por: Choi, Hyungwook, et al.
Publicado: (2023)

Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma
por: Ahmed, Hussain Gadelkarim, et al.
Publicado: (2011)

Occurrence of Neuroblastoma among TP53 p.R337H Carriers
por: Seidinger, Ana Luiza, et al.
Publicado: (2015)

Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2023)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

FOXL2 and FOXA1 cooperatively assemble on the TP53 promoter in alternative dimer configurations
por: Choi, Yuri, et al.
Publicado: (2022)

TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
por: Lee, Eung Bae, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8cclk2iidd327a8a8uv7u5rr8d